NEW YORK and ANN ARBOR, Mich., Mar. 13, 2017 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today that Pablo J. Cagnoni, M.D., has been elected to the Company’s Board of Directors, effective immediately. The Company also announced that Timothy M. Mayleben will step down from his position on… Read More

First-In-Class RORgamma Agonist to Begin Phase 1 – Dose Finding and Safety Assessment NEW YORK and ANN ARBOR, Mich., January 4, 2017 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the initiation of a Phase 1/2a clinical trial of the Company’s novel immuno-oncology therapeutic candidate LYC-55716, in patients… Read More

First-In-Class Oral ATPase Modulator in Randomized Study Designed to Demonstrate Safety and Efficacy NEW YORK and ANN ARBOR, Mich., December 7, 2016 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the initiation of a Phase 2 clinical trial of the Company’s lead therapeutic candidate, LYC-30937-Enteric Coated, in patients… Read More

NEW YORK and ANN ARBOR, Mich., Nov. 10, 2016 — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced the expansion of its scientific advisory board (SAB) to include 11 renowned clinical researchers and scientists. The Company, which recently announced the initiation of its Phase 2 clinical trial of therapeutic… Read More

NEW YORK and ANN ARBOR, Mich., November 4, 2016 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the publication of new research findings for the Company’s most advanced cancer immunotherapy program: oral, selective RORgamma agonists.  RORgamma is a nuclear receptor transcription factor that serves as a master control… Read More

First-In-Class ATPase Modulator in Randomized Study Designed to Demonstrate Clinical Remission NEW YORK and ANN ARBOR, Mich., August 22, 2016 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the initiation of a Phase 2 clinical trial of the Company’s lead clinical-stage candidate, LYC-30937-Enteric Coated, in patients with ulcerative… Read More

Dr. Toogood Recognized for His Contributions to Innovation in the Treatment of Metastatic Breast Cancer NEW YORK and ANN ARBOR, Mich., Aug. 3, 2016 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today that Peter L. Toogood, Ph.D., Lycera’s Senior Vice President, Chemistry and Chemical Biology has received the… Read More

NEW YORK and ANN ARBOR, Mich., April 19, 2016 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today that research findings from the Company’s RORgamma agonist program were presented at this week’s annual meeting of the American Association for Cancer Research (AACR), which is taking place in New Orleans,… Read More

— As reported in an oral presentation, findings demonstrated selective activity of LYC-30937 against chronically activated, disease-causing immune cells while sparing normal cells in preclinical disease models and assays   — In a separate poster presentation a highly selective inhibitor of Rho kinase 2 showed broad anti-fibrotic activity in in preclinical assays NEW YORK and… Read More

NEW YORK and ANN ARBOR, Mich., Jan. 11, 2016 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today that it entered into a license agreement with its collaboration partner Celgene Corporation.  Under the agreement, Lycera granted to Celgene an exclusive license for Lycera’s portfolio of novel ex vivoRORgamma agonist… Read More